Yingqiang Liu

发表

Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders.

Lin-jiang Tong, Youhong Hu, Li-Fan Zeng, 2020, Journal of medicinal chemistry.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Pharmacology.

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

K. Yu, Yi Chen, Jian Ding, 2023, Journal of Cancer.

Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.

Honglin Li, Zhenjiang Zhao, Jian Ding, 2019, Bioorganic & medicinal chemistry.

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Kai Yu, Yi Chen, Jian Ding, 2021, Cancer science.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Lin-jiang Tong, Hua Xie, Yan-yan Shen, 2023, Acta pharmaceutica Sinica. B.

ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Drug Discovery.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

Lin-jiang Tong, Huancheng Zhou, Gang Bai, 2024, Signal transduction and targeted therapy.